IRMD — iRadimed Corporation

Is IRMD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Neutral As of November 17, 2026

iRadimed Corporation (IRMD) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $84.84. The rating moved from Oversold to Neutral on November 6, 2026.

AI analysis

iRadimed operates in a specialized medtech niche with an established installed base of MRI‑compatible infusion and monitoring systems, generating recurring revenue from consumables and service. Financial visibility typically hinges on replacement cycles and hospital capital spending; absent large new contracts or product launches, near‑term performance is likely to track procedure volumes and sales execution. Strengths include a focused product offering and sticky customer relationships in imaging departments. Key concerns are small‑cap liquidity, client concentration, and device regulatory/reimbursement risks. Market sentiment in the recent window was muted and risk‑on toward defensives, which neither materially aids nor impairs the company in the short term. Reasonable scenarios include stable modest growth driven by replacement demand and distribution expansion, upside from broader adoption or new products, and downside if large orders are delayed or competitive/regulatory headwinds intensify.

Key factors

  • Niche position in MRI‑compatible infusion pumps and monitoring equipment with a durable installed base among imaging centers and hospitals
  • Recurring revenue potential from consumables, service contracts and replacement cycles supports revenue visibility
  • Relatively limited exposure to broad pharma/GLP‑1 market moves; demand driven by imaging and interventional procedure volumes
  • Low near‑term volatility in the market window reduces macro noise, enabling focus on company‑level execution and sales cadence
  • Potential for upside from new product introductions, distribution expansion, or increased hospital capital spending

Risks

  • Small‑cap company risks: limited liquidity, higher stock volatility, and greater sensitivity to single large orders or contract timing
  • Concentration risk from a narrow product portfolio and dependence on a limited number of large hospital or distributor customers
  • Regulatory and product liability risks inherent to medical devices, including clearance/approval delays or adverse events
  • Reimbursement and purchasing budget pressures at hospitals and imaging centers, particularly if macro/policy environment tightens capital spending
  • Competitive risk from larger medtech firms or lower‑cost entrants offering alternative infusion or monitoring solutions

See today's live rating, score and targets

Members see the live hourly rating for IRMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.